Ki67 and PR to predict sensitivity of palbociclib: A real-world study.

e13032Background: Palbociclib combined with endocrine therapy are approved as a front-line treatment for hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC). A key challenge ...